Hearing function of paediatric patients with cancer in Johannesburg, South Africa: relationships and influences explored

Abstract

According to the World Health Organization (WHO), there are about 466 million people living with a disabling hearing loss globally, with almost 34 million of them being children, and approximately 7 million of these children are living in Sub-Saharan Africa (SSA). In South Africa, the incidence of childhood cancer represents approximately 1% of all cancers in the population. The standard treatment in South Africa consists of platinum compounds such as cisplatin and carboplatin. Morbidity factors amongst childhood cancer survivors include hearing loss. Between 20% and 70% of patients suffer from cisplatin and carboplatinum-related ototoxicity. In any context including the South African context, for preventive audiology, it is important to describe and characterise the hearing function of paediatric patients with cancer. Aim: The main aim of the current study was to investigate the hearing function of paediatric patients with cancer in Johannesburg, South Africa. Methodology: A descriptive retrospective record review design was adopted in this study. The patient records were reviewed from Chris Hani Baragwanath Academic Hospital and Charlotte Maxeke Johannesburg Academic Hospital oncology and audiology units. Non- proportional quota sampling was used in this study. Data was reviewed from 47 patient records from the Chris Hani Baragwanath Academic Hospital and Charlotte Maxeke Johannesburg Academic Hospital audiology and oncology units. Analysis: In this current study, descriptive and inferential statistics were used in order to indicate any patterns the data may have assumed and to help summarise the collected data. Findings: Demographic and diagnostic factors were thought to have an influence on the hearing function of the paediatric population with cancer. When establishing if a relationship existed between age of diagnosis, gender, race, type of cancer, treatment duration, and type of treatment and hearing function, all the objectives were found to be statistically non-significant, except for the type of cancer which was found to have a statistically significant association. The researcher was 95% 8 confident that the true prevalence of hearing loss in the paediatric population with cancer would fall between 23.5% and 51.2%. The prevalence of hearing loss was found to be 36.2%. Conclusion: The participants who were found to have a hearing impairment, had a hearing impairment due to ototoxicity. As evident from all the audiological assessments administered, there was an evident change in the hearing function of participants from session one to two. Implications: It was recommended by the researcher that audiological monitoring as well as screening protocols be implemented in the oncology and audiology units. Current findings could contribute towards identifying risk factors that are associated with hearing loss in the paediatric population with cancer. These findings could possibly help guide future researchers, audiologists, pharmacists, oncologists, or policy makers in in developing treatment protocols, policies and interventions that may help minimize the effects and risks of cancer treatment on the hearing function of this population without having to compromise the effectiveness of their treatment. Implications for future research are also raised by current findings.